NYSE$HIMS
Hims & Hers Health Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported first quarter results with revenue surpassing $100 million and a significant increase in member subscriptions.
Hims & Hers Health, Inc. reported strong first-quarter 2022 results, with revenue reaching $101.3 million, up 94% year-over-year. The company also experienced its largest-ever quarterly gain in member subscriptions, increasing by 101,000 to a total of 710,000. The company raises full year 2022 revenue guidance to the range of $410.0 million to $425.0 million and maintains Adjusted EBITDA guidance in the range of $(30.0) million to $(20.0) million
- Revenue for Q1 2022 reached $101.3 million, a 94% increase year-over-year.
- The company added 101,000 new subscriptions in Q1 2022.
- Hims & Hers ended Q1 2022 with 710,000 subscriptions, up 82% year-over-year.
- Full year 2022 revenue guidance raised to $410 - $425 million.
Headline financials
Revenue & EPS history
Hims & Hers · Revenue · Quarterly
$101M
Revenue by segment
Hims & Hers · $101M total across 2 segments · Q1 2022
- Online Revenue$94.1M+85.7%92.9%
- Wholesale Revenue$7.21M+341.4%7.1%
Forward guidance
For the second quarter 2022, we expect: Revenue to be in the range of $103 million to $106 million. Adjusted EBITDA to be in the range of $(9) million to $(7) million, which would reflect an Adjusted EBITDA margin in the range of (9)% to (7)%. For the full year 2022, we expect: Revenue to be in the range of $410 million to $425 million. Adjusted EBITDA to be in the range of $(30) million to $(20) million, which would reflect an Adjusted EBITDA margin in the range of (7)% to (5)%.
Tailwinds
- Revenue to be in the range of $103 million to $106 million for Q2 2022
- Adjusted EBITDA to be in the range of $(9) million to $(7) million for Q2 2022
- Revenue to be in the range of $410 million to $425 million for FY 2022
- Adjusted EBITDA to be in the range of $(30) million to $(20) million for FY 2022
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+2.5%
Avg return
Earnings day
+3.8%
Avg return
5 days after
+11.7%
Avg return
30 days after
50%
13 / 26 earnings
Positive
+41.1%
Q4 2023
Best reaction
-22.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.0% | -11.4% | -1.8% | |
| Q4 2025 | -2.8% | -6.4% | +34.5% | |
| Q3 2025 | -3.6% | -7.6% | -9.8% | |
| Q1 2025 | +18.5% | +24.1% | +26.0% | |
| Q4 2024 | -22.3% | -12.1% | -37.8% | |
| Q3 2024 | +1.4% | +15.0% | +66.6% | |
| Q2 2024 | -4.0% | -9.2% | -16.9% | |
| Q1 2024 | +9.7% | +9.1% | +93.2% | |
| Q4 2023 | +41.1% | +37.8% | +65.3% | |
| Q3 2023 | +7.6% | +5.1% | +37.3% | |
| Q2 2023 | -8.7% | -11.7% | -15.2% | |
| Q1 2023 | -11.5% | -10.2% | -23.9% | |
| Q4 2022 | +15.4% | +6.0% | +2.7% | |
| Q3 2022 | +30.1% | +37.2% | +64.7% | |
| Q2 2022 | -3.4% | +9.2% | -0.6% | |
| Q1 2022 | -13.0% | -13.5% | +5.3% | |
| Q4 2021 | +8.0% | +20.5% | +19.8% | |
| Q3 2021 | -7.0% | -1.3% | -26.3% | |
| Q2 2021 | +7.0% | -4.7% | +11.1% | |
| Q1 2021 | +13.7% | +44.9% | +33.1% | |
| Q2 2020 | -8.4% | -7.2% | -21.9% | |
| Q4 2020 | -7.5% | -15.4% | -21.3% | |
| Q3 2020 | +0.1% | +0.0% | +17.5% | |
| Q1 2020 | -0.7% | -0.5% | +0.1% | |
| Q4 2019 | +1.4% | +2.1% | +2.2% | |
| Q3 2019 | +0.0% | +0.3% | -0.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro